Company Overview and News

 
Immediate hurdle for Notion at 74.5 sen, says AllianceDBS Research

2018-10-01 theedgemarkets
KUALA LUMPUR (Oct 2): AllianceDBS Research said Notion VTec Bhd (Notion) had on Oct 1 tested last Friday’s high of 74.5 sen before closing near the day’s low at 73 sen (up 0.5 sen or 0.69%).
0083

 
Notion active, rises 1.38% on accepting insurance settlement

2018-10-01 theedgemarkets
KUALA LUMPUR (Oct 1): Notion VTec Bhd shares rose 1.38% in active trade this morning after it accepted AXA Affin General Insurance Bhd's RM159.37 million claim settlement offers to Notion VTec's wholly-owned subsidiary Notion Venture Sdn Bhd following a fire incident at Notion VTec's main plant in Klang, Selangor.
0083

 
KLCI expected to start fourth quarter on a subdued note

2018-09-30 theedgemarkets
KUALA LUMPUR (Oct 1): The FBM KLCI is expected to commence the final quarter of 2018 on a subdued note today as market participants await more directions from finance minister Lim Guan Eng when he tables Budget 2019 on Nov 2.
4634 5843 2127 7158 0083 5184 5268 8583 5256

 
Notion VTec accepts insurance settlement of RM159.37mil

2018-09-28 thestar.com.my
KUALA LUMPUR: Notion VTec Bhd has accepted from its insurer a full and final claim settlement of RM159.37mil for material fire losses in the incident that occurred at its main manufacturing plant in Klang.
0083

 
Notion VTec, IRIS, Sapura Energy, Mah Sing, Scomi, Pos Malaysia, Reach Energy, Cypark, Comfort Gloves, Gamuda, KPS, Berjaya Corp, MyEG and Ikhmas Jaya

2018-09-28 theedgemarkets
KUALA LUMPUR (Sept 28): Based on corporate announcements and news flow today, companies in focus on Monday (Oct 1) may include: Notion VTec Bhd, IRIS Corp Bhd, Sapura Energy Bhd, Mah Sing Group Bhd, Scomi Group Bhd, Pos Malaysia Bhd, Reach Energy Bhd, Cypark Resources Bhd, Comfort Gloves Bhd, Gamuda Bhd, Kumpulan Perangsang Selangor Bhd (KPS), Berjaya Corp Bhd (BCorp), My EG Services Bhd (MyEG) and Ikhmas Jaya Group Bhd.
4634 5843 2127 7158 0083 5184 5268 8583 5256

 
AWC, Opensys, Amverton, Deleum, Keck Seng, Lii Hen, Minho, Ni Hsin, Notion VTec, Pinehill

2018-09-26 theedgemarkets
KUALA LUMPUR (Sept 26): theedgemarkets.com highlighted 10 stocks with momentum at Bursa Malaysia’s afternoon market close today. Two showed positive momentum while eight had negative momentum.
3476 0083 BSMAF 1818

 
KLCI claws back to erase loss, Tenaga lifts

2018-09-26 theedgemarkets
KUALA LUMPUR (Sept 26): The FBM KLCI clawed back to erase its earlier losses at the midday break today, powered by gains at Tenaga Nasional Bhd and other select index-linked blue chips.
7084 7060 7036 0083 BATS 4162 7765 1163 5256 9334 5199 0154 KLKBY 5029 2445 5347 5258 3026 7216 TNABY 2836 TNABF HIPEF 1929

 
Bioalpha, Karyon, Taliworks, Minho, Notion VTec, Redtone, SHL

2018-08-24 theedgemarkets
KUALA LUMPUR (Aug 24): theedgemarkets.com highlighted seven stocks with momentum at Bursa Malaysia’s afternoon market close today. Three stocks displayed positive momentum while four showed negative momentum.
0083 BSMAF 1818

 
Notion taking a breather, says AllianceDBS Research

2018-08-06 theedgemarkets
KUALA LUMPUR (Aug 7): AllianceDBS Research said Notion VTec Bhd (Notion) had on Aug 6 traded within last Friday’s range to form an inside day bar before closing at the day’s low of 59.5 sen (down 1.5 sen or 2.45%).
0083

 
Renewed buying interest emerged in Notion, says AllianceDBS Research

2018-08-02 theedgemarkets
KUALA LUMPUR (Aug 3): AllianceDBS Research said Notion Vtec Bhd (Notion) had on Aug 2 crossed over the 59.5 sen hurdle to reach an intraday high of 61.5 seb before settling at 60 sen (up 3.5 sen or 6.19%).
0083

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...